Spots Global Cancer Trial Database for Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)
Study ID: NCT00060476
Conditions
Study Description
Brief Summary: To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
Detailed Description: The duration of treatment is 6 years.
Keywords
Eligibility
Minimum Age: 50 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Contact Details
Name: Medical Monitor
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
